Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 2, 2016, Pages 107-126

  Darquenne, Chantal ^a   Fleming, John S ^b,c   Katz, Ira ^d,e   Martin, Andrew R ^f   Schroeter, Jeffry ^g   Usmani, Omar S ^h   Venegas, Jose ⁱ   Schmid, Otmar ^j,k  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b National Institute of Health Research Biomedical Research Unit in Respiratory Disease   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d AIR LIQUIDE   (France)

^e LAFAYETTE COLLEGE   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g APPLIED RESEARCH ASSOCIATES   (United States)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j German Center for Lung Research   (Germany)

^k INSTITUTE OF EPIDEMIOLOGY   (Germany)

more..

Author keywords

aerosol deposition distribution; Biological lung models; In silico lung modeling; PET; SPECT

Indexed keywords

AEROSOL; AEROSOL DEPOSITION DISTRIBUTION; AIRWAY; ARTICLE; ARTIFICIAL VENTILATION; BASIC RESEARCH; BIOLOGICAL MODEL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; INHALATION FLOW RATE; LUNG; LUNG MODEL; MEDICAL SOCIETY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; RESPIRATORY TRACT PARAMETERS; SCIENCE; SCINTISCANNING; SIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WETTABILITY; ANATOMIC MODEL; ANATOMY AND HISTOLOGY; BREATHING; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; CONSENSUS; CONSENSUS DEVELOPMENT; DIAGNOSTIC IMAGING; DRUG FORMULATION; INHALATIONAL DRUG ADMINISTRATION; MEDICAL RESEARCH; PHYSIOLOGY; STANDARDS;

AEROSOL; DRUG;

ADMINISTRATION, INHALATION; AEROSOLS; BIOMEDICAL RESEARCH; CONSENSUS; DRUG COMPOUNDING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG; MODELS, ANATOMIC; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; RESPIRATION;

EID: 84964776829     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2015.1270     Document Type: Article

References (157)

1. Darquenne C: Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25:140-147.
2. Labiris NR, and Dolovich MB: Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588-599.
3. Carrigy NB, Martin AR, and Finlay WH: Use of extrathoracic deposition models for patient-specific dose estimation during inhaler design. Curr Pharm Design. 2015; 21:3984-3992.
4. Lahzami S, and King GG: Targeting small airways in asthma: The new challenge of inhaled corticosteroid treatment. Eur Respir J. 2008;31:1145-1147.
5. Weibel ER, Sapoval B, and Filoche M: Design of peripheral airways for efficient gas exchange. Resp Physiol Neurobiol. 2005;148:3-21.
6. Weibel ER: Morphometry of the Human Lung. New York: Academic Press, 1963.
7. Darquenne C. Deposition of aerosols in the lung: Deposition mechanisms. In: Dhand R, ed. Textbook of Aerosol Medicine. Knoxville (TN): International Society for Aerosols in Medicine, 2015:e1-16.
8. Selting K, Essman S, Reinero C, Branson KR, Henry CJ, Owen N, Guntur VP, Waldrep JC, Kim DY, and Dhand R: Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading. J Aerosol Med Pulm Drug Deliv. 2011;24:43-48.
9. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, Henry C, Owen N, Madsen R, and Dhand R: Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the Aero Probe® intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv. 2008;21:255-268.
10. Crowder T, Rosati J, Schroeter J, Hickey A, and Martonen T: Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res. 2002;19:239-245.
11. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, Eberbeck D, Bittmann I, Bergemann C, Weyh T, Trahms L, Rosenecker J, and Rudolph C: Targeted delivery of magnetic aerosol droplets to the lung. Nat Nano. 2007;2:495-499.
12. Martin AR, and Finlay WH: Enhanced deposition of high aspect ratio aerosols in small airway bifurcations using magnetic field alignment. J Aerosol Sci. 2008;39:679-690.
13. Redman GES, Martin AR, Waszak P, Thompson RB, Cheung P-Y, Thebaud B, and Finlay WH: Pilot study of inhaled aerosols targeted via magnetic alignment of high aspect ratio particles in rabbits. J Nanomater. 2011;article ID: 130621, 7 pgs.
14. Martin AR. Regional deposition: Targeting. In: Dhand R, ed. Textbook of Aerosol Medicine. Knoxville (TN): International Society for Aerosols in Medicine, 2015:e1-24.
15. Borgstrom L, Olsson B, and Thorsson L: Degree of throat deposition can explain variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
16. Weers JG, Clark AR, Rao N, Ung K, Haynes A, Khindri SK, Perry SA, Machineni S, and Colthorpe P: In vitro-in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler. J Aerosol Med Pulm Drug Deliv. 2015;28:268-280.
17. Brand P, Hederer B, Austen G, Dewberry H, and Meyer T: Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J COPD. 2008;3:763-770.
18. Dalby R, Spallek M, and Voshaar T: A review of the development of Respimat((R)) Soft Mist (TM) Inhaler. Int J Pharm. 2004;283:1-9.
19. Shemirani FM, Hoe S, Lewis D, Church T, Vehring R, and Finlay WH: In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs. J Aerosol Med Pulm Drug Deliv. 2013;26:215-222.
20. Grgic B, Martin AR, and Finlay WH: The effect of unsteady flow rate increase on in vitro mouth-throat deposition of inhaled boluses. J Aerosol Sci. 2006;37:1222-1233.
21. Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, Olsson B, Thiel CG, Wachtel H, and Finlay WH: In vivo-in vitro correlations: Predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23:S59-S69.
22. Finlay WH, Stapleton KW, and Zuberbuhler P: Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J Aerosol Med. 1998;11:65-80.
23. Finlay WH: Estimating the type of hygroscopic behavior exhibited by aqueous droplets. J Aerosol Med. 1998;11: 221-229.
24. Stahlhofen W, Rudolf G, and James AC: Intercomparison of experimental regional aerosol deposition data. J Aerosol Med. 1989;2:285-308.
25. Dolovich MA: Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care. 2000;45:597-608.
26. Laube BL, Jashani R, Dalby RN, and Zeitlin PL: Targeting aerosol deposition in patients with cystic fibrosis. Chest. 2000;118:1069-1076.
27. Zeman KL, Wu J, and Bennett WD: Targeting aerosolized drugs to the conducting airways using very large particles and extremely slow inhalations. J Aerosol Med Pulm Drug Deliv. 2010;23:363-369.
28. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, and Weers JG: Improved lung delivery from a passive dry powder inhaler using an engineered Pulmo Sphere (R) powder. Pharm Res. 2002;19:689-695.
29. DeLong M, Wright J, Dawson M, Meyer T, Sommerer K, and Dunbar C: Dose delivery characteristics of the AIR (R) pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452-459.
30. Hoe S, Traini D, Chan HK, and Young PM: The influence of flow rate on the Aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm Res. 2009;26:2639-2646.
31. Stein SW, and Myrdal PB: The relative influence of atomization and evaporation on metered dose inhaler drug delivery efficiency. Aerosol Sci Tech. 2006;40:335-347.
32. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, and Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593-604.
33. Fischer A, Stegemann J, Scheuch G, and Siekmeier R: Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res. 2009;14:71-77.
34. Denyer J, and Dyche T: The adaptive aerosol delivery (AAD) technology: Past, present, and future. J Aerosol Med Pulm Drug Deliv. 2010;23:S1-S10.
35. Clark AR, and Hartman M: Regional lung deposition: Can it be controlled and have an impact on safety and efficacy? Respir Drug Deliv. 2012;1:89-100.
36. Clark AR, Chambers CB, Muir D, Newhouse MT, Paboojian S, and Schuler C: The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5 mu m) bolus aerosols. J Aerosol Med. 2007;20:75-82.
37. Otis AB, McKerrow CB, Bartlett RA, Mead J, McIlroy MB, Selverstone NJ, and Radford EP, Jr.: Mechanical factors in distribution of pulmonary ventilation. J Appl Physiol. 1956;8:427-443.
38. Bennett WD, Brown JS, Zeman KL, Hu SC, Scheuch G, and Sommerer K: Targeting delivery of aerosols to different lung regions. J Aerosol Med. 2002;15:179-188.
39. Martin AR, and Finlay WH: The effect of humidity on the size of particles delivered from metered-dose inhalers. Aerosol Sci Tech. 2005;39:283-289.
40. Hindle M, and Longest PW: Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol. 2012; 64:1254-1263.
41. Tian G, Longest PW, Li X, and Hindle M: Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv. 2013;26:248-265.
42. Javaheri E, and Finlay WH: Size manipulation of hygroscopic saline droplets: Application to respiratory drug delivery. Int J Heat Mass Transf. 2013;67:690-695.
43. Hess DR, Fink JB, Venkataraman ST, Kim IK, Myers TR, and Tano BD: The history and physics of heliox. Respir Care. 2006;51:608-612.
44. Katz I, Pichelin M, Montesantos S, Majoral C, Martin A, Conway J, Fleming J, Venegas J, Greenblatt E, and Caillibotte G: Using helium-oxygen to improve regional deposition of inhaled particles: Mechanical principles. J Aerosol Med Pulm Drug Deliv. 2014;27:71-80.
45. Peterson JB, Prisk GK, and Darquenne C: Aerosol deposition in the human lung periphery is increased by reduceddensity gas breathing. J Aerosol Med Pulm Drug Deliv. 2008;21:159-168.
46. Anderson M, Svartengren M, Bylin G, Philipson K, and Camner P: Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis. 1993; 147: 524-528.
47. Svartengren M, Anderson M, Philipson K, and Camner P: Human lung deposition of particles suspended in air or in helium/oxygen mixtures. Exp Lung Res. 1989;15:575-585.
48. Swift DL, Carpin JC, and Mitzner W: Pulmonary penetration and deposition of aerosols in different gases: Fluid flow effects. Ann Occup Hyg. 1982;26:109-117.
49. Darquenne C, and Prisk GK: Aerosol deposition in the human respiratory tract breathing air and 80:20 heliox. J Aerosol Med. 2004;17:278-285.
50. Kim IK, Phrampus E, Sikes K, Pendleton J, Saville A, Corcoran T, Gracely E, and Venkataraman S: Heliumoxygen therapy for infants With bronchiolitis. Arch Pediatr Adolesc Med. 2011;165:1115-1122.
51. Kress JP: The utility of albuterol nebulized with Heliox during acute asthma exarcerbations. Am J Resp Crit Care Med. 2002;165:1317-1321.
52. deBoisblanc BP, DeBleiux P, Resweber S, Fusco EE, and Summer WR: Randomized trial of the use of heliox as a driving gas for updraft nebulization of bronchodilators in the emergent treatment of acute exacerbations of chronic obsructuve pulmonary disease. Crit Care Med. 2000;28: 3177-3180.
53. El-Khatib MF, Jamaleddine G, Kanj N, Zeineddine S, Chami H, Bou-Akl I, Husari A, Alawieh M, and Bou-Khalil P: Effect of heliox-and air-driven nebulized bronchodilator therapy on lung function in patients with asthma. Lung. 2014;192:377-383.
54. Kim IK, and Corcoran T: Recent developments in heliox therapy for asthma and bronchiolitis. Clin Pediatr Emerg Med. 2009;10.
55. Fleming J, Conway J, Majoral C, Katz I, Caillibotte G, Pichelin M, Montesantos S, and Bennett M: Controlled, parametric, individualized, 2-D and 3-D imaging measurements of aerosol deposition in the respiratory tract of asthmatic human subjects for model validation. J Aerosol Med Pulm Drug Deliv. 2015;28:432-451.
56. EP. European Pharmacopoeia (EP) 5.1-Section 2.9.18 Preparations for Inhalation: Aerodynamic Assessment of Fine Particles. 2005:2799-2811.
57. Burnell PKP, Asking L, Borgstrom L, Nichols SC, Olsson B, Prime D, and Shrubb I: Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV. The oropharyngeal retention effectfor four inhalation delivery systems. J Aerosol Med. 2007;20:269-281.
58. Delvadia RR, Longest PW, and Byron PR: In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm Drug Deliv. 2012; 25:32-40.
59. Stapelton KW, Guentsch E, Hoskinson MK, and Finlay WH: On the suitability of the j-e turbulence modeling for aerosol deposition in the mouth and throat: A comparison with experiment. J Aerosol Sci. 2000;31:739-749.
60. Weers JG, Clark AR, Rao N, Ung K, Haynes A, Khindri SK, Perry SA, Machineni S, and Colthorpe P: In vitro-in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler. J Aerosol Med Pulm Drug Deliv. 2015;28:268-280.
61. Cochrane MG, Bala MV, Downs KE, Mauskopf J, and Ben-Joseph RH: Inhaled corticosteroids for asthma therapy: Patient compliance, devices, and inhalation technique. Chest. 2000;117:542-550.
62. Carrigy NB, Ruzycki CA, Golshahi L, and Finlay WH: Pediatric in vitro and in silico models of deposition via oral and nasal inhalation. J Aerosol Med Pulm Drug Deliv. 2014;27:149-169.
63. Grgic B, Finlay WH, Burnell PKP, and Heenan AF: In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci. 2004;35:1025-1040.
64. Ruzycki CA, Golshahi L, Vehring R, and Finlay WH: Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children. Pharm Res. 2014;31:1525-1535.
65. Walenga RL, Longest PW, and Sundaresan G: Creation of an in vitro biomechanical model of the trachea using rapid prototyping. J Biomech. 2014;47:1861-1868.
66. Mitchell JP, and Suggett JA: Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: The need for clinically appropriate testing. Aaps Pharmscitech. 2014;15:1275-1291.
67. Delvadia RR, Wei X, Longest PW, Venitz J, and Byron PR: In vitro tests for aerosol deposition. IV: Simulating variations in human breath profiles for realistic DPI testing. J Aerosol Med Pulm Drug Deliv. in press.
68. Olsson B, Borgstrom L, Lundback H, and Svensson M: Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Deliv. 2013; 26:355-369.
69. Rudolf G, Kîbrich R, and Stahlhofen W: Modelling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci. 1990;21:S403-S406.
70. Finlay WH, and Martin AR: Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv. 2008;21:189-206.
71. Martonen T, Rosati J, and Isaacs K. Modeling deposition of inhaled particles Aerosols Hand Book: Measurement, Dosimetry, and Health Effects. Boca Raton, FL: CRC Press, 2005:113-125.
72. Heyder J, Gebhart J, Rudolf G, Schiller CF, and Stahlhofen W: Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J Aerosol Sci. 1986; 17:811-825.
73. Conway J, Fleming J, Majoral C, Katz I, Perchet D, Peebles C, Tossici-Bolt L, Collier L, Caillibotte G, Pichelin M, Sauret-Jackson V, Martonen T, Apiou-Sbirlea G, Muellinger B, Kroneberg P, Gleske J, Scheuch G, Texereau J, Martin A, Montesantos S, and Bennett M: Controlled, parametric, individualized, 2-D and 3-D imaging measurements of aerosol deposition in the respiratory tract of healthy human subjects for model validation. J Aerosol Sci. 2012;52:1-17.
74. Hofmann W: Modeling inhaled particle deposition in the human lung: A review. J Aerosol Sci. 2011;42:693-724.
75. Kleinstreuer C, and Zhang Z: Laminar-to-turbulent fluidparticle flows in a human airway model. Int J Multiphase Flow. 2003;29:271-289.
76. Zhang Z, Kleinstreuer C, and Kim CS: Flow structure and particle transport in a triple bifurcation airway model. J Fluids Engineering-T ASME. 2001;123:320-330.
77. Zhang Y, Finlay WH, and Matida EA: Particle deposition measurements and numerical simulation in a highly idealized mouth-throat. J Aerosol Sci. 2004;35:789-803.
78. Xi J, Longest PW, and Martonen TB: Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approxiamte model of the upper tracheobronchial airways. J Appl Physiol. 2008;104:1761-1777.
79. Gemci T, Ponyavin V, Chen Y, Chen H, and Collins R: Computational model of airflow in upper 17 generations of human respiratory tract. J Biomech. 2008;41:2047-2054.
80. Corley RA, Kabilan S, Kuprat AP, Carson JP, Minard KR, Jacob RE, Timchalk C, Glenny RW, Pipavath S, Cox T, Wallis CD, Larson RF, Fanucchi MV, Postlethwait EM, Einstein DR: Comparative computational modeling of airflows and vapor dosimetry in the respiratory tracts of rat, monkey, and human. Toxicol Sci. 2012;128:500-516.
81. Jayaraju ST, Brouns M, Verbanck S, and Lacor C: Fluid flow and particle deposition analysis in a realistic extrathoracic airway model using unstructured grids. J Aerosol Sci. 2007;38:494-508.
82. Ley S, Mayer D, Brook BS, van Beek EJ, Heussel CP, Rinck D, Hose R, Markstaller K, and Kauczor HU: Radiological imaging as the basis for a simulation software of ventilation in the tracheo-bronchial tree. Eur Radiol. 2002;12:2218-2228.
83. Ma B, and Lutchen KR: CFD simulation of aerosol deposition in an anatomically based human large-medium airway model. Ann Biomed Eng. 2009;37:271-285.
84. Kuprat AP, Kabilan S, Carson JP, Corley RA, and Einstein DR: A bidirectional coupling procedure applied to multiscale respiratory modeling. J Comput Phys. 2013;244.
85. Oakes JM, Marsden A, Grandmont C, Shadden SC, Darquenne C, and Vignon-Clementel IE: Airflow and particle deposition simulations in health and emphysema: from invivo to in-silico animal experiments. Ann Biomed Eng. 2014;42:899-914.
86. De Backer JW, Vos WG, Vinchurkar SC, Claes R, Drollmann A, Wulfrank D, Parizel PM, Germonpre P, and De Backer W: Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257:854-862.
87. Wongviriyawong C, Harris RS, Greenblatt E, Winkler T, and Venegas JG: Peripheral resistance: A link between global airflow obstruction and regional ventilation distribution. J Appl Physiol. 2013;114:504-514.
88. Katz I, Pichelin M, Caillibotte G, Montesantos S, Majoral C, Martonen T, Fleming J, Bennett M, and Conway J: Controlled, parametric, individualized, 2d, and 3d imaging measurements of aerosol deposition in the respiratory tract of healthy human subjects: preliminary comparisons with simulations. Aerosol Sci Tech. 2013;47:714-723.
89. Scheinherr A, Bailly L, Boiron O, Legou T, Giovanni A, Caillibotte G, and Pichelin M: Glottal motion and its impact on the respiratory flow. Comput Methods Biomech Biomed Engin. 2012;15:69-71.
90. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W, Ruegg M, Schwalenstocker B, Stiller D, van den Berg L, Vieira F, and von Horsten S: Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Sci. 2010;11:38-45.
91. Hahn C, and Erb KJ: The preclinical testing strategy for the development of novel chemical entities for the treatment of asthma. Cur Drug Targets. 2008;9:443-451.
92. Mullane K, and Williams M: Animal models of asthma: Reprise or reboot? Biochem Pharmacol. 2014;87:131-139.
93. Nahar K, Gupta N, Gauvin R, Absar S, Patel B, Gupta V, Khademhosseini A, and Ahsan F: In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci. 2013;49:805-818.
94. Hittinger M, Juntke J, Kletting S, Schneider-Daum N, Carvalho CD, and Lehr CM: Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv Drug Deliv Rev. 2015;85:44-56.
95. Mercer PF, Abbott-Banner K, Adcock IM, and Knowles RG: Translational models of lung disease. Clin Sci. 2015; 128:235-256.
96. Fernandes CA, and Vanbever R: Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv. 2009;6: 1231-1245.
97. Harrison F, Muruli A, Higgins S, and Diggle SP: Development of an ex vivo porcine lung model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. Infect Immun. 2014;82:3312-3323.
98. Beck-Broichsitter M, Schmehl T, Seeger W, and Gessler T: Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models. J Nanomater. 2011;16 pgs. DOI: 10.1155/2011/163791.
99. Uhl FE, Vierkotten S, Wagner DE, Burgstaller G, Costa R, Koch I, Lindner M, Meiners S, Eickelberg O, and Konigshoff M: Preclinical validation and imaging of Wntinduced repair in human 3D lung tissue cultures. Eur Respir J. 2015;46:1150-1166.
100. Paur H-R, Cassee FR, Teeguarden J, Fissan H, Diabate S, Aufderheide M, Kreyling WG, Hänninen O, Kasper G, Riediker M, Rothen-Rutishauser B, and Schmid O: Invitro cell exposure studies for the assessment of nanoparticle toxicity in the lung. A dialog between aerosol science and biology. J Aerosol Sci. 2011;42:668-692.
101. Nichols JE, Niles JA, Vega SP, Argueta LB, Eastaway A, and Cortiella J: Modeling the lung: Design and development of tissue engineered macro and micro-physiologic lung models for research use. Exp Biol Med. 2014;239: 1135-1169.
102. Blank F, Rothen-Rutishauser B, and Gehr P: Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am J Respir Cell Mol Biol. 2007;36:669-677.
103. Lenz AG, Karg E, Brendel E, Hinze-Heyn H, Maier KL, Eickelberg O, Stoeger T, and Schmid O: Inflammatory and oxidative stress responses of an alveolar epithelial cell line to airborne zinc oxide nanoparticles at the air-liquid interface: A comparison with conventional, submerged cellculture conditions. Biomed Res Intl. 2013:2013:652632.
104. Vlahakis NE, Schroeder MA, Limper AH, and Hubmayr RD: Stretch induces cytokine release by alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol. 1999; 277:L167-L173.
105. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, and Ingber DE: Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662-1668.
106. Lenz AG, Karg E, Lentner B, Dittrich V, Brandenberger C, Rothen-Rutishauser B, Schulz H, Ferron GA, and Schmid O: A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part Fibre Toxicol. 2009;6:32.
107. Lenz AG, Stoeger T, Cei D, Schmidmeir M, Semren N, Burgstaller G, Lentner B, Eickelberg O, Meiners S, and Schmid O: Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in airliquid interface conditions. Am J Respir Cell Mol Biol. 2014;51:526-535.
108. Wick P, Chortarea S, Guenat OT, Roesslein M, Stucki JD, Hirn S, Petri-Fink A, and Rothen-Rutishauser B: In vitroex vivo model systems for nanosafety assessment. Eur J Nanomed. 2015;7:169-179.
109. Huh D, Hamilton GA, and Ingber DE: From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011;21: 745-754.
110. Deng X, Li Y, and Qiu J: Human bocavirus 1 infects commercially available primary human airway epithelium cultures productively. J Virol Methods. 2014;195:112-119.
111. Sauer UG, Vogel S, Hess A, Kolle SN, Ma-Hock L, van Ravenzwaay B, and Landsiedel R: In vivo-in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems. Toxicol in Vitro. 2013;27: 174-190.
112. Alepee N, Bahinski A, Daneshian M, De Weyer B, Fritsche E, Goldberg A, Hansmann J, Hartung T, Haycock J, Hogberg HT, Hoelting L, Kelm JM, Kadereit S, McVey E, Landsiedel R, Leist M, Luebberstedt M, Noor F, Pellevoisin C, Petersohn D, Pfannenbecker U, Reisinger K, Ramirez T, Rothen-Rutishauser B, Schaefer-Korting M, Zeilinger K, and Zurich M-G: State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. Altex-Altern Animal Ex. 2014;31:441-477.
113. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, Gavrilov K, Yi T, Zhuang ZW, Breuer C, Herzog E, and Niklason LE: Tissue-engineered lungs for in vivo implantation. Science. 2010;329:538-541.
114. Venegas JG, Winkler T, Musch G, Melo MFV, Layfield D, Tgavalekos N, Fischman AJ, Callahan RJ, Bellani G, and Harris RS: Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature. 2005;434:777-782.
115. Greenblatt EE, Winkler T, Harris RS, Kelly VJ, Kone M, and Venegas J: Analysis of three-dimensional aerosol deposition in pharmacologically relevant terms: beyond black or white ROIs. J Aerosol Med Pulm Drug Deliv. 2015;28:116-129.
116. Dolovich MB: Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med. 2001; 14:S35-44.
117. Newman S. In vivo assessment Respiratory Drug Delivery, Essential Theory and Practice. Richmond: RDD online, 2009:103-116.
118. Dolovich MB, and Bailey DL: Positron emission tomography (PET) for assessing aerosol deposition of orally inhaled drug products. J Aerosol Med Pulm Drug Deliv. 2012;25:S52-71.
119. Laube BL, Corcoran TE, Devadason SG, Dolovich MB, Fleming J, and Newman S: Standards for lung imaging techniques. J Aerosol Med Pulm Drug Deliv. 2012;25:S1-S2.
120. Thompson RB, and Darquenne C. Magnetic resonance imaging of aerosol deposition. In: Dhand R, ed. Textbook of Aerosol Medicine. Knoxville (TN): International Society for Aerosols in Medicine, 2015:e1-20.
121. Thompson RB, and Finlay WH: Using MRI to measure aerosol deposition. J Aerosol Med Pulm Drug Deliv. 2012; 25:55-62.
122. Pitcairn GR, and Newman SP: Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med. 1997;10:187-198.
123. Fleming JS, Conway JH, Bolt L, and Holgate ST: A comparison of planar scintigraphy and SPECT measurement of total lung deposition of inhaled aerosol. J Aerosol Med. 2003;16:9-19.
124. Laube BL, Edwards AM, Dalby RN, Creticos PS, and Norman PS: The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. J Allergy Clin Immunol. 1998;101:475-483.
125. Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, Fleming G, Haeussermann S, Kietzig C, Kuelh PJ, Laube BL, Sommerer K, Taylor G, Usmani OS, and Zeman KL: Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25:10-28.
126. Usmani OS, Biddiscombe MF, and Barnes PJ: Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497-1504.
127. Phipps PR, Gonda I, Bailey DL, Borham P, Bautovich G, and Anderson SD: Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis. 1989;139:1516-1523.
128. Fleming JS, Halson P, Conway J, Moore E, Nassim MA, Hashish AH, Bailey AG, Holgate ST, and Martonen TB: Three-dimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging. J Nucl Med. 1996;37:873-877.
129. Venegas J, Winkler T, and Harris RS: Lung physiology and aerosol deposition imaged with positron emission tomography. J Aerosol Med Pulm Drug Deliv. 2013;26:1-8.
130. Berridge MS, Lee Z, and Heald DL: Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J Nucl Med. 2000;41:1603-1611.
131. Fleming JS, Nassim M, Hashish AH, Bailey AG, Conway J, Holgate S, Halson P, Moore E, and Martonen TB: Description of pulmonary deposition of radiolabeled aerosol by airway generation using a conceptual three-dimensional model of lung morphology. J Aerosol Med. 1995;8:341-356.
132. Fleming J, Bailey DL, Chan HK, Conway J, Kuehl PJ, Laube BL, and Newman S: Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25:S29-51.
133. Berker Y, Goedicke A, Kemerink GJ, Aach T, and Schweizer B: Activity quantification combining conjugateview planar scintigraphies and SPECT/CT data for patientspecific 3-D dosimetry in radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:2173-2185.
134. Rousset OG, Ma Y, and Evans AC: Correction for partial volume effects in PET: Principle and validation. J Nucl Med. 1998;39:904-911.
135. Fleming JS, Sauret V, Conway JH, Holgate ST, Bailey AG, and Martonen TB: Evaluation of the accuracy and precision of lung aerosol deposition measurements from single-photon emission computed tomography using simulation. J Aerosol Med. 2000;13:187-198.
136. Fleming J, Conway J, Majoral C, Tossici-Bolt L, Katz I, Caillibotte G, Perchet D, Pichelin M, Muellinger B, Martonen T, Kroneberg P, and Apiou-Sbirlea G: The use of combined single photon emission computed tomography and x-ray computed tomography to assess the fate of inhaled aerosol. J Aerosol Med Pulm Drug Deliv. 2011;24:49-60.
137. Robertson HT, Glenny RW, Stanford D, McInnes LN, Luchtel DL, and Covert D: High-resolution maps of regional ventilation utilizing inhaled fluorescent microspheres. J Appl Physiol. 1997;82:943-953.
138. Miyawaki S, Tawhai MH, Hoffman EA, and Lin CL: Effect of carrier gas properties on aerosol distribution in a CT-based human airway numerical model. Ann Biomed Eng. 2012;40:1495-1507.
139. de Vasconcelos TF, Sapoval B, Andrade JS, Grotberg JB, and Filoche M: Particle capture into the lung made simple? J Appl Physiol. 2011;110:1664-1673.
140. Chan TL, and Lippmann M: Experimental measurement and empirical modeling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J. 1980; 41:399-409.
141. Darquenne C, van Ertbruggen C, and Prisk GK: Convective flow dominates aerosol delivery to the lung segments. J Appl Physiol. 2011;111:48-54.
142. Kim CS, Hu SC, DeWitt P, and Gerrity TR: Assessment of regional deposition of inhaled particles in human lungs by serial bolus delivery method. J Appl Physiol. 1996;81: 2203-2213.
143. Greenblatt EE, Winkler T, Harris RS, Kelly VJ, Kone M, Katz I, Martin AR, Caillibotte G, and Venegas J: What causes uneven aerosol deposition in the bronchoconstricted lung? A quantitative imaging study. J Aerosol Med Pulm Drug Deliv. in press.
144. Usmani OS: Treating the small airways. Respiration. 2012;84:441-453.
145. Usmani OS: Small-airway disease in asthma: Pharmacological considerations. Curr Opin Pulm Med. 2015;21:55-67.
146. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, and Barnes PJ: Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol. 2003;95:2106-2112.
147. Usmani OS, Biddiscombe MF, Underwood SR, and Barnes PJ: Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. J Nucl Med. 2004;45:69-73.
148. Biddiscombe MF, Meah SN, Underwood SR, and Usmani OS: Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J Aerosol Med Pulm Drug Deliv. 2011;24:165-173.
149. Usmani OS, and Barnes PJ: Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44:146-156.
150. Nicolini G, Scichilone N, Bizzi A, Papi A, and Fabbri LM: Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations. Ther Clin Risk Manag. 2008;4:855-864.
151. Newman S, Salmon A, Nave R, and Drollmann A: High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100:375-384.
152. Hoshino M: Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int. 2010;-59:59-66.
153. Leach CL, Davidson PJ, and Boudreau RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353.
154. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, and Bousquet J: Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41-49.
155. Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, and Pauwels R: Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005; 18:328-336.
156. Barnes NC, Jones PW, and Davis KJ: Safety of tiotropium through the Handihaler: Why did meta-analyses and database studies appear to give a false alarm? Thorax. 2014; 69:598-599.
157. Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L, Peterkin V, and Disse B: Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54:405-414.